

Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency

H.H. Abdul-Razak¹⁺, C.J. Rocca¹⁺, S.J. Howe^{2,3}, M.E. Alonso-Ferrero², J. Wang⁴, R. Gabriel⁵, C.C. Bartholomae⁵, C.H.V. Gan², M.I. Garín⁶, A. Roberts⁷, M.P. Blundell², V. Prakash¹, F.J. Molina-Estevez^{1,6}, J. Pantoglou¹, G. Guenechea⁶, M.C. Holmes⁴, P.D. Gregory⁴, C. Kinnon², C. von Kalle⁵, M. Schmidt⁵, J.A. Bueren⁶, A.J. Thrasher^{2,8} and R.J Yáñez-Muñoz^{1,*}

¹AGCTlab.org, Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway, University of London, Egham, UK.

²Infection, Immunity, Inflammation and Physiological Medicine Programme, Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.

³Gene Transfer Technology Group, UCL Institute for Women's Health, University College London, London, UK.

⁴Sangamo Therapeutics, Inc., Richmond, California, USA.

⁵Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.

⁶Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCI3)/Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid. Spain.

⁷Department of Medical and Molecular Genetics, King's College London, London, UK.

⁸Great Ormond Street Hospital NHS Foundation Trust, London, UK.

*rafael.yanez@royalholloway.ac.uk

+these authors contributed equally to this work

SUPPLEMENTARY INFORMATION

Supplementary Table 1 | Animal groups used in transplantation experiment.

Group #	Group name	Donor cells (male)	MOI	Recipients (female)
1	wt control	BALB/c OlaHsd	-	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i>
2	eGFP control	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i> transduced with CMV-eGFP-WPRE IPLV	400	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i>
3	IPLV	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i> transduced with IPLV ZFN monomers and IDLV template.	100: 100: 200	BALB/c JHan (tm)Hsd- <i>Prkdc scid</i>
4	IDLV	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i> transduced with IDLVs template/CMV ZFN1 and template/CMV ZFN2	500: 500	BALB/c JHan(tm)Hsd- <i>Prkdc scid</i>

Supplementary Table 2 | SELEX amplicons for off-target analysis

Rank	Name	Score	Chromosome	Location	Site	Mismatch (bp)	Arrangement (Left ZFN / Gap / Right ZFN)	Left_Primer	Right_Primer	Amplicon Length (bp)
1	On-target	8.22E-11	chr16	15839293	GGGCCAaCCCaGCTGTATAACITGGtaAGACTTGT	5	17834 / 6 / 17373_1bpSKIP	TGAGCAGACAATGCTGAGAAA	AACAGACAAGGGTGTGAGCC	301
2	Off-target 1	1.33E-11	chr4	136870923	CtcCtGcCCcCCcCAAGCCcCCAGGATGAC TTGG	5	17834 / 5 / 17373_1bpSKIP	ACTTCACCAATCACCCAGC	ATCTCAGCATTCAACACC	303
3	Off-target 2	8.03E-12	chr15	91433193	CCAAGTCCATCCAGGTTTAGGaCHGtGTGGggG	5	17373_1bpSKIP / 5 / 17834	GGGAAGGAAAGGCAATCTCT	GCTGACTATGAGGACGAGG	387
4	Off-target 3	6.01E-12	chr7	117849399	CaGtGTCTATCCaAGTTGCCTTggaGAGGTGGCCT	5	17373_1bpSKIP / 5 / 17834	CcAAACTGGGAATGGCTGT	GAGCACTAAGCTGGGGAG	327
5	Off-target 4	4.82E-12	chr7	90098094	GCAAGTCTAaCCAGGTGTGGCTGCGGGaaTGGCtC	4	17373_1bpSKIP / 5 / 17834	TTGTTCTGACGATGCTCTG	AGCTGGAGACAAGGAACA	341
6	Off-target 5	4.35E-12	chr6	85095172	ACAGGaCagTCAGGTGGGAGAGCtGGGGaGGCtA	5	17373_1bpSKIP / 5 / 17834	CAGCTTTAGGGCCTTTTGC	TC TTCACACCTCCCTGCTT	314
7	Off-target 6	2.45E-12	chr15	98526028	CgGAGTCTATcGTGGTGGCGCGCGGcGGTGGCgG	4	17373_1bpSKIP / 6 / 17834	CTGGACACAGACCC TGGATT	GTAACCTGGCTTCTGGA	300
8	Off-target 7	2.07E-12	chr1	91082864	GaGCCACCTCtGaCTGCtACCAGGAtAgcCTGT	4	17834 / 5 / 17373_1bpSKIP	CGATGGCTGAATGTATGCAC	TGTGTATATAGGTGGGGC	300
9	Off-target 8	2.02E-12	chr13	45481996	CaGCCtCCCTCtCCAGCGCACcAGGAgAaACCTGG	5	17834 / 6 / 17373_1bpSKIP	CGGTGGGTTTTCTATTCCCT	CTTCACAAAGCAGAAAGCGTG	360
10	Off-target 9	1.84E-12	chr6	39217052	GtGCCAaCCcAagTTcTATcACCTGGAcTGAcATGG	7	17834 / 6 / 17373_1bpSKIP	AGGCCTGCATCTGTATGACC	ACAAAGGTATGCCAGACAGGA	383
11	Off-target 10	1.74E-12	chr8	11441154	AGGCCACCCcCCcCAACaCaTGGATAGgCTGA	4	17834 / 6 / 17373_1bpSKIP	CTACCATGCTCTGTGGCA	GGCTACTACCTGGGGTTCC	335


Supplementary Table 3 | MiSeq adaptor PCR primers

Target	Chrom	Location	Forward Primer†	Reverse Primer#
On-Target	chr16	15839293	CGGAAAAGAATTGGTATCCAC	CTGCTCAGAAGTGTGTGAAGTGC
Off-target 1	chr4	136870923	GCTTCAGTCATTACACGCC	CTCAGCCATTCAACACCCC
Off-target 2	chr15	91433193	GGAGAGGAAGTCTTCCACGG	GAAACCTTCTGTGGCAACCC
Off-target 3	chr7	117849399	CCTGTCAGGTCTGGAGGGTA	AAGGTTCTTGAATGAAGTTGGG
Off-target 4	chr7	90098094	GCTGCACTGATGGGTCTGGT	GTTTCATGCTTGGCTCATTCC
Off-target 5	chr6	85095172	CCCTTCCTGCCTGGGATTT	GCTAAAGGAGGAGGAGGAGGAG
Off-target 6	chr15	98526028	GCTACCAGAACAATGTCCCTG	CTCAACCTGGCAGAGATCCAC
Off-target 7	chr1	91082864	GAGACCTCAGTCACGGTTCATT	GACACTTGCTGTAGACAAAGAAGG
Off-target 8	chr13	45481996	GGAAGAAATGACAGGAGGGAAG	GTTAAAAGCAGAAGGCCAGG
Off-target 9	chr6	39217052	CCCAGAATCCACATACAAAACA	GCATGAGGAGGTCAGAGGTC
Off-target 10	chr8	11441154	GCGACTGCCTCAGTTTCTCTAC	GGTCTCCATGAGCATCAACACC

† Forward primer sequence: 5'- CTTTCCCTACACGACGCTCTCCGATCTnnnnn - followed by target-specific sequences as listed.


Reverse primer sequence: 5'- GACGTGTGCTCTTCCGATCT - followed by target-specific sequences as listed.

Supplementary Figure 1




Supplementary Figure 1 | Genomic *Prkdc* sequence flanking *scid* site after genome editing. Indicated are the gene editing template (red sequence), the *scid* site showing the wild-type sequence, the location where the engineered diagnostic *Bsa*WI site was introduced, the binding sites for the ZFN monomers and predicted cut site, as well as forward (F) and reverse (R) PCR primers for *Bsa*WI assay (also used for deep sequencing), amplification of the 1.6 kb targeting template and indel *Cel*-I assay.

Supplementary Figure 2




Supplementary Figure 2 | Schematic of lentiviral plasmid constructs. Plasmid backbones are not shown. Abbreviations: RSV, Rous sarcoma virus promoter; CMV, immediate early cytomegalovirus promoter; SFFV, Spleen focus-forming virus LTR promoter; RU5, 3'end of HIV long terminal repeat (LTR), including repeat (R) and unique 5 (U5) regions; PBS, primer binding site; RRE, rev response element; ψ , encapsidation signal; cPPT/cTS, central polypurine tract/central termination sequence; ZFN1 and ZFN2, Zinc-Finger Nuclease monomer open reading frames including N-terminal triple FLAG epitopes; WPRE, Woodchuck hepatitis virus post-transcriptional regulatory element; 3'dLTR, HIV LTR with self-inactivating (SIN) internal deletion within unique 3 (U3) region that essentially eliminates promoter activity, making gene expression in the resulting provirus dependent on an internal promoter; *Prkdc*, repair template, cloned in reverse orientation to prevent splicing of exon 85 during the lentiviral vector RNA stage.

Supplementary Figure 3




Supplementary Figure 3 | Schematic of *neo Prkdc* gene editing PCR assay. Following gene editing with the plasmid-based *neo*-containing template, genomic DNA was extracted and PCR amplified using a forward primer internal to *neo* and a reverse primer downstream from 3' homology arm. PCR products were separated by gel electrophoresis, before or after digestion with suitable enzymes. A 1.3 kb, digested by *Hind*III, *Bgl*II and *Xho*I, is diagnostic for gene targeting.

Supplementary Figure 4




Supplementary Figure 4 | Schematic of *Prkdc* gene editing *Bsa*WI assay. Following gene editing, genomic DNA was extracted and PCR amplified using primers shown on Supplementary, Figure 1. Amplicons were digested with *Bsa*WI, separated by gel electrophoresis, blotted, transferred onto nylon membrane, hybridised with radio-labelled probe (the original PCR product) and imaged. U: Unrepaired, R: Repaired. The presence of 1 and 0.64 kbp bands is diagnostic for gene editing; in practice the 0.64 kbp band is difficult to visualise against low molecular weight smear so we only rely on 1 kb band for quantification of gene editing frequency.

Supplementary Figure 5



Supplementary Figure 5 | Viability of balb/c and *scid* fibroblasts after melphalan treatment. *mTert scid* and balb/c fibroblasts were exposed to melphalan for 1 h and cultured for 5 further days in drug-free medium, before an MTT assay to determine cell viability.

Supplementary Figure 6



Supplementary Figure 6 | *Prkdc* gene editing in *scid* fibroblasts. The uncropped gel from Figure 2b is shown. Cells were transduced with IPLV-ZFN/IDLV-template or IDLV-ZFN/template at the indicated MOI and with ZFN genes driven by the indicated promoters, and genomic DNA was extracted 10 d post-transduction. *Scid* locus was PCR-amplified with primers external to template, and ZFN-mediated gene correction was quantified from the diagnostic *Bsa*WI band (arrow) and shown as %*Prkdc* correction. LV denotes standard integration-proficient lentiviral vector (IPLV).